Lilly raises outlook for third time this year as Zepbound sales soar
The GLP-1 drug continues to dominate the market for prescription weight-loss drugs in the U.S.
The GLP-1 drug continues to dominate the market for prescription weight-loss drugs in the U.S. This story matters for Finance & Markets readers tracking currency. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. CurrencyNews.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily currency signal